SOFIA VIDAURRE MENDES

Medical Oncology MD 🫁🇧🇷

[Abeid Athman (Omar). @bin_abeid]

THE CONQUER STUDY

We, the @ASCO IDEA Awardees 2024 are conducting a worldwide survey on the use of oncology guidelines. Please help us fill our survey for us to share the results in #ASCO2025 https://t.co/rmUZqzwvS6 @jrgralow @curijoey @stolaney1 @OncoAlert @DrSGraff @tmprowell

[GBOT Alerta @GBOT_Alerta]

🦋 MARIPOSA #PressRelease - resultado positivo SG!
- Amivantamabe + Lazertinibe vs Osimertinibe
❗️Benefício SG (⬆️SGm >1a).
🤔Qual a magnitude do beneficio? Qual o Tto pós-PD no braço controle?
- Aguardamos apresentação e publicação dos dados! #GBOT
https://t.co/m9pWFkkz3X

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

🚨📣Attention to early career professionals in #ThoracicOncology.

Deadline to apply for the 2025 @IASLC #Academy is approaching (Nov 30).

The #Academy offers exclusive #mentorship & guidance, essential skill-building, and chance to attend #WCLC25.

👇🏼
https://t.co/DFzdoyx8VZ

[Narjust Florez, MD, FASCO @NarjustFlorezMD]

Friends that have the same goal - improve the care of all patients with thoracic malignancies

At 2024 @IASLC Latin America Lung Cancer Conference

#LALCA24

[SOFIA VIDAURRE MENDES @vidaurremendes]

Had an amazing time at LALCA 2024 in Bogotá! Fantastic discussions and an excellent opportunity to connect with colleagues in Thoracic Oncology. Looking forward to the next one! #LALCA2024
@LuisRaezMD @cbaldotto @clarissamathias @LuciaViola9 @LealTiciana @BrunaPellini @Latinamd

[Camila Braganca Xavier @CamilaBragancaX]

Visiting Brazil & contributing to society is the best mix! Panel on clinical research opportunities & the path of training abroad at @SBOC_Oncologia 2024 w/ the great Fabio Franke, @rdienstmann, @mirella_nardo & the young oncologists committee colleagues @vidaurremendes & Cecilia

[SOFIA VIDAURRE MENDES @vidaurremendes]

Young Oncologist session #SBOC24
Thanks Dr @GlopesMd for the amazing lesson about social media!

[Felippe Lazar @felippelazar]

👉🏼 Finding available cancer trials in Brazil is a thought task and most hem-oncs will end up asking friends.

I recently began an open and collaborative data project of showcasing these trials built on top of the clinicaltrialsGov database - https://t.co/HbCq2bQD5p 1/n

[SOFIA VIDAURRE MENDES @vidaurremendes]

IASLC Academy 2024 was a great opportunity to exchange experiences and develop research with people from all over the world. Special thanks to my mentor @LuisRaezMD for all the support. Congratulations IASLC for the initiative!
#wclc24

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

🚨🔥The future of #ThoracicOncology is in GREAT hands!

The final meeting of the 2024 @IASLC #Academy with this OUTSTANDING group of #EarlyCareer #Physicians & #Researchers at #WCLC24.

Honored to serve as academy co-chair with my amazing friend @ChristianRolfo & GREAT faculty.

[Dr. Luis E. Raez @LuisRaezMD]

Faculty and meentees of
our @IASLC academy that is meeting today at #WCLC24 with @ChristianRolfo @RManochakian @DrSteveMartin @lungoncdoc
@triparnasen @marinagarassino @LudaBazhenovaMD @JPatelMD @ADesaiMD and many others! #lungcancer #lcsm @vidaurremendes

[GBOT Alerta @GBOT_Alerta]

🇧🇷🫁Estudo Brasileiro unicêntrico - perfil molecular N=119 CPCNP não tabagistas (LCNIS).
- 73% AGAs
- Mutação mais comum EGFR (49,6%) TP53 (39,5%); Comutação: 27,7%
- Fusão ALK (12,6%): ⬆️ frequência (3-8%)
- Demais alterações: ↔️ dados 🌎
@vidaurremendes #GBOTjovem
@OncoAlert

[Amalya Sargsyan @amalsargsyan]

Absolutely recommended workshop for every young researcher! 📊Life-changing experience, interactions with superb faculty and lasting connections🤩

Superstars joining #teamCREDO ?

@Elen_Baloyan @bin_abeid @elbairikhalid19 @KariSh313
@myrette_s @kinjal_majumdar @vidaurremendes

[GBOT Alerta @GBOT_Alerta]

📢 Publicado ontem no NEJM resultados do estudo #MARIPOSA. Lazertinibe + Amivantamabe vs Osimertinibe ou Lazertinibe na 1L CPNPC EGFR+.
- ✅ EP 1 (Laze+Ami vs Osi): ⬆️SLP 23.7x16.6m (HR 0.7).
- Benefício às custas ⬆️ EAs (G3: 75x43%). #GBOTjovem @vidaurremendes

[Amalya Sargsyan @amalsargsyan]

Wrapping up our #ASCO24 with the most enthusiastic, smart, friendly and inspiring group of IDEA awardees!

Read our joint article led by @elbairikhalid19 in ASCO post

https://t.co/Iqb5hGN9Br

Special thanks to Vanessa & Vanessa & Ariella 🥰

[Dr. Luis E. Raez @LuisRaezMD]

Our @IASLC Academy is meeting today again!!, very happy to help young oncologists at the begining of their career! @RManochakian #LCSM @christ #LungCancer @FawziAbuRous @esinghimd @kaushalpar @ADesaiMD @vidaurremendes @RamilaShilpakar @drdaviddwlee @Ritalepp @DrSteveMartin @acmoorephd @triparnasen @JenniferCKing @LudaBazhenovaMD @JessicaJLinMD @marinagarassino @JPatelMD
@Piuchagarrido @AnneTsao2 @ZerAlona
@FedericoCappuz1 @ElinardouHelena
@PranshuMohindra @HwakeleeMD @ChristianRolfo

[SOFIA VIDAURRE MENDES @vidaurremendes]

@LuisRaezMD @IASLC @RManochakian @christ @FawziAbuRous @kaushalpar @ADesaiMD @RamilaShilpakar @drdaviddwlee @Ritalepp @DrSteveMartin @acmoorephd It’s an honor to have you as my mentor, Dr Raez!

[GBOT Alerta @GBOT_Alerta]

❗️Estudo publicado no JCO mostra disparidades raciais e étnicas no cuidado de fim de vida em pcts com câncer de 🫁
- Análise dados populacional: 207.429 (2005-2018)
- Pretos e hispânicos: ⬆️tratamentos invasivos✖️brancos não hispânicos
@vidaurremendes
https://t.co/Xw03Q10zeZ

[GBOT Alerta @GBOT_Alerta]

📢 Publicado no @NEJM estudo fase III ALINA.
Pcts CPNPC 🫁 ressecado ALK + EC IB (>4cm), II e IIIA
- 257 randomizados
- Alectinibe x doublet de platina adjuvante
✅ Benefício expressivo em SLD (HR 0.24), ainda sem dados de SG.
‼️ Resultados animadores.
https://t.co/R6NQyL78uX